Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma - PubMed
3 hours ago
- #Nasopharyngeal Carcinoma
- #EBV Biomarkers
- #Diagnostic Performance
- The study evaluated the diagnostic performance of the anti-EBV BNLF2b total antibody (P85-Ab) assay for suspected nasopharyngeal carcinoma (NPC) in outpatient settings.
- P85-Ab demonstrated superior diagnostic performance with a sensitivity of 93.0% and specificity of 97.3%, outperforming other EBV-related biomarkers.
- The study included 3777 participants (1680 with NPC and 2097 without NPC) across 5 medical centers in China.
- P85-Ab maintained high sensitivity among asymptomatic individuals (92.0%) and those with NPC-nonspecific symptoms (88.4%).
- For NPC-specific symptoms, combining P85-Ab with VCA-IgA and EBNA1-IgA improved sensitivity compared to P85-Ab alone (95.9% vs 93.1%).
- The findings suggest P85-Ab as a robust biomarker for NPC detection, with tailored approaches for different symptom presentations.